318 filings
Page 8 of 16
8-K
85kxv
16 Mar 15
Anthera Pharmaceuticals Reports 2014 Fourth Quarter and Fiscal Year Financial Results, Operational Update and Recent Event Highlights
12:00am
424B5
hqrb7 mqxx2
16 Mar 15
Prospectus supplement for primary offering
12:00am
8-K
5u1qpu60re4zma4wfe8
16 Mar 15
Entry into a Material Definitive Agreement
12:00am
8-K
dl9lrivsb3zodq7ta37y
11 Feb 15
Anthera Pharmaceuticals Announces Completion of Interim Analysis from Phase 3 Trial with Blisibimod for Systemic Lupus Erythematosus
12:00am
8-K
to20akvx51680zp 8uf
28 Jan 15
Entry into a Material Definitive Agreement
12:00am
424B5
cgfg66bze 40
28 Jan 15
Prospectus supplement for primary offering
12:00am
8-K
q3g7lk5z6eds o81
7 Jan 15
Anthera Pharmaceuticals Announces Appointment of Klara A. Dickinson as Senior Vice President, Chief Regulatory Officer
12:00am
8-K
f1n0jhr
30 Dec 14
Termination of a Material Definitive Agreement
12:00am
8-K
9o5suny xgaqhv
24 Dec 14
Other Events
12:00am
CT ORDER
ybl79 ue30q1ib0nlb
16 Dec 14
Confidential treatment order
12:00am
8-K
adti1 o43td4
16 Dec 14
Entry into a Material Definitive Agreement
12:00am
8-K
y3ml7t6v zgoip4cc
21 Nov 14
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
12:00am
8-K
bv1uawq01rs3qsm xyt
14 Nov 14
Anthera Pharmaceuticals Reports 2014 Third Quarter Financial Results
12:00am
8-K
tho6jhfjpo5lm4dp40b5
23 Oct 14
Termination of a Material Definitive Agreement
12:00am
8-K
sx5fb
1 Oct 14
Anthera Pharmaceuticals Announces Update on Strategic Partnership Discussions for Blisibimod
12:00am
POS AM
fiwvbipq7d1o0bebo
26 Sep 14
Prospectus update (post-effective amendment)
12:00am